风险提示： 贸易局势不确定性，国内稳增长政策不及预期 。 >>以上内容节选自国泰海通证券已经发布的研究报告 ： 消费和基建有韧性 ，具体分析内容（包括风险提示等） 请详见完 整版报告。 【 海外科技 】谷歌发布Gemini 2.5 Pro I/O，特朗普政府拟取消AI扩散框架 投资建议： 维持行业增持评级，推荐 AI 算力方向、云厂商方向、 AI 应用方向、 AI 社交方向以及 AI 注 入周期下的中概巨头。 谷歌发布 Gemini2.5 Pro （ I/O 版）， AI 助力前端开发与复杂编程。 为预热 I/O 全球开发者大会，谷 歌发布" I/O Edition "特别预览版 Gemini 2.5 Pro 模型，专门面向开发者群体，主要优化了日常编程任 务，支持创建基于智能体的工作流程。谷歌此次更新的一大亮点在于，只需通过一条提示即可构建完整、 可交互的网页应用或模拟程序。谷歌表示，用户可以输入视觉模式或主题性提示，直接转化为可运行的代 码，这显著降低了设计导向型开发者或创新团队的入门门槛。在 WebDev Arena 基准测试中， Gemini 2.5 Pro 凭借出色的前端开发能力位居榜首。模型在视频 ...

Company Overview - Beijing Hotgen Biotech Co., Ltd. focuses on innovative biotechnology, providing solutions from early disease screening and diagnosis to treatment [1] - The main products include in vitro diagnostic products and innovative biopharmaceuticals [1] Financial Performance - For Q1 2025, the company reported revenue of 93.24 million yuan, a year-on-year decrease of 19.71% [1] - The net profit for the same period was -24,008,215.62 yuan, reflecting a year-on-year decline of 574.96% [1] - The gross profit margin stood at 47.27% [1] Market Position - As of the latest report, Hotgen Biotech's closing price was 103.5 yuan, down 5.39%, with a price-to-book ratio of 3.21 and a total market capitalization of 9.571 billion yuan [1] - A total of 55 institutions hold shares in Hotgen Biotech, including 52 funds, with a combined holding of 28.6952 million shares valued at 2.741 billion yuan [1] Industry Comparison - The company's price-to-earnings (P/E) ratio (TTM) is -43.49, while the industry average is 49.84 [2] - The industry median P/E ratio is 36.59, indicating that Hotgen Biotech is significantly underperforming compared to its peers [2]

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 凯杰公布了2 0 2 5年第一季度的财务状况，销售额为4 . 8 3亿美元，与去年同期的4 . 5 9亿美元相比，同比上涨了5%。 这主要是由于广泛的 效率提高和2 0 2 4年决定停止使用Ne uMoDx临床PCR检测系统，调整后的营业利润率提高了4 . 1个百分点，达到2 9 . 8%。调整后的摊薄每股收益 （EPS）为0 . 5 5美元，0 . 5 6美元的每股收益超过了至少0 . 5 0美元的每股收益预期。 导读： 近日，凯杰公布了2025年第一季度的财务状况，销售额为4.83亿美元，与去年同期的4.59亿美元相比，同比上涨了5%。 鉴于2 0 2 5年第一季度的业绩，以及持续的宏观趋势（包括美国和中国的进口关税），QIAGEN重申其2 0 2 5财年净销售预期约为4%（核心销售 增长约为5%）。调整后每股收益预期在4月份上调至约2 . 3 5美元。凯杰还重申了2 0 2 5年调整后的营业利润率目标为3 0%以上，并预计将达到至 少3 1%的中期利润率目标，远早于原定的 ...

5月12日，科华生物今日收盘6.09元，下跌4.25%，最新市净率0.96，总市值31.32亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)29科华生物-4.71-4.890.9631.32亿行业平均 49.8445.684.61105.51亿行业中值36.5938.052.4346.93亿1天益医疗-1742.06-2983.951.8622.20亿2澳华内 镜-602.36302.124.8363.48亿3诺唯赞-409.62-484.482.2587.66亿4爱朋医疗-362.84275.654.3729.77亿5博晖 创新-324.04514.213.4647.54亿6硕世生物-131.86-1926.851.1838.57亿7奥精医疗-125.28-183.621.6523.25亿 8睿昂基因-99.99-82.091.4212.94亿9康泰医学-84.67-71.543.0255.73亿10中红医疗-70.88-56.530.9049.26亿 11华大智造-59.73-53.004.11318.43亿 截至2025年一季报，共有5家机构持仓科华生物，其中其他5家，合计持股数11465 ...

智通财经记者 | 李科文 智通财经编辑 | 谢欣 5月10日，达安基因发布第八届董事会2025年第三次临时会议决议公告。会议以7票赞成，2票反对，0票弃权的表决结果审议通过了达安基因第九届董事会换 届议案。 黄志征、韦典含、朱琬瑜、陈宏威、张为结、梁志坤成为达安基因第九届董事会非独立董事候选人。除韦典含外，第八届董事会其余成员全部被替换，其中 也包括现任董事长薛哲强。 薛哲强其实也来自达安基因大股东广州金控，因此，替换薛哲强也是大股东层面的决定，薛哲强对此并无反对意见。而黄志征、韦典含、朱琬瑜、陈宏威、 张为结都来自广州金控背景。梁志坤则来自达安基因内部，也是未来董事会唯一技术背景出身，是达安基因体外诊断研发平台总监。 但是，这次换届还是暴露出广州金控入主达安基因后，股东与旧管理层的不和谐。此次换届，两张反对票来自黄珞与张斌。这两人都已在达安基因管理层任 职超10年。 二人认为新一届董事会及经营团队"高度同质化，以纯金融背景为主"，缺乏具有体外诊断（IVD）行业前瞻技术与商业战略能力的领导者。 在持续的产品降价和竞争压力中，和同类公司相比，达安基因却走了一条与行业众多企业都不相同的第二增长曲线。 不过，实际上 ...

Group 1 - Baichuan Energy plans to reduce its shareholding by up to 26.82 million shares, accounting for 2% of the total share capital, due to personal investment and funding needs [1] - Jinhong Gas intends to distribute a cash dividend of 1.00 yuan per 10 shares, with the record date on May 15, 2025 [2] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1% of the total share capital due to liquidity needs [2][3] Group 2 - Jiadu Technology will cancel 10.20 million repurchased shares, reducing its total share capital from 2.143 billion shares to 2.133 billion shares [4] - ILE Home's shareholder plans to reduce its stake by up to 154,250 shares, accounting for 0.4778% of the total share capital, due to funding needs [5] - Lai Yifen has fully removed related batches of its honey date dumpling products from shelves due to consumer health concerns [6][7] Group 3 - CATL's vice chairman Li Ping and spouse plan to donate 4.05 million shares to Fudan University for establishing a research fund, reducing Li Ping's shareholding from 4.58% to 4.48% [8] - Shuanghuan Transmission's shareholders completed their reduction plan, selling a total of 6.69 million shares, accounting for 0.789% of the total share capital [9] - Chengfei Integration reported no significant changes in its business operations or external environment despite stock price fluctuations [10] Group 4 - Guizhou Tire's controlling shareholder plans to increase its stake by no less than 50 million yuan and no more than 100 million yuan within six months [11] - *ST Youshu's application to revoke the delisting risk warning has been approved, and its stock will resume trading under a new name [13] - Jingwei Huikai's shareholders plan to reduce their stake by up to 3% of the total share capital due to funding needs [14] Group 5 - Hualan Biological's major shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [15] - Huyou Pharmaceutical's shareholder plans to reduce its stake by up to 2.997% of the total share capital due to funding needs [16] - Dongpeng Holdings' shareholders plan to reduce their stake by up to 1.5% of the total share capital due to funding needs [17] Group 6 - Keleke's controlling shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [18] - Dongfang Ocean's major shareholder plans to reduce its stake by 1% of the total share capital due to investor redemption requests [19] - Yisheng Shares reported a sales revenue of 141 million yuan from white feather chicken seedlings in April, with a year-on-year decrease of 7.28% [20] Group 7 - Qujiang Cultural Tourism's controlling shareholder's 12 million shares are set to be auctioned due to contractual disputes, representing 4.70% of the total share capital [21] - Duople's shareholder plans to reduce its stake by up to 123,800 shares, accounting for 2% of the total share capital, due to personal funding needs [22][23]

核心产品GASTROClear™是全球市场上唯一一款获批准进行胃癌筛查的分子诊断IVD产 品。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， Mirxes Holding Company Limited （以下简称 "觅瑞"）日前通过港交所聆 讯并于5月12日披露通过聆讯后的资料集，中金公司和建银国际担任联席保荐人。 成立于 2014年 的觅瑞作为 一家微小核糖核酸（「 miRNA」）技术公司，致力于使疾病筛查诊断 解决方案在亚洲关键市场（包括新加坡及中国）触手可及。 截至 2025 年 5 月 7 日 ， 觅 瑞 有 一 种 核 心 产 品 ( 即 GASTROClear™) 、 两 种 其 他 商 业 化 产 品 (即 LungClear™ 及 Fortitude™) 以 及 六 种 处 于 临 床 前 阶 段 的 候 选 产 品 。 其 中 ， 核 心 产 品 GASTROClear™ 是 一个由 12种miRNA生物 标志物 组成的用于胃癌筛查的基于血液的 miRNA检 测组 ，其已于 2019年5月获得新加坡卫生科学局的C类体外诊断 ...

[Table_Author] 分析师：王俐媛 1) 周度回顾。上周（4 月 28 日-5 月 9 日）医药生物板块 收涨 1.5%，跑输 wind 全 A（2.32%）和沪深 300（1.56%）。 从板块来看，线下药店（5.64%）、医疗设备（4.49%） 和医疗研发外包（2.78%）涨幅居前，疫苗（-0.45%）、 血液制品（-0.43%）和体外诊断（-0.17%）跌幅居前。 从个股来看，常山药业（26.28%）、海创药业（25.85%） 减肥药概念涨幅居前。 2) 减肥药重要性再度提升。5月7日，世界卫生组织(WHO) 回应称，自 2022 年以来，世卫组织一直在针对不同年 龄组（儿童、青少年和成年人）制定一套关于肥胖预 防、护理和治疗的新指南。关于使用 GLP-1 药物和 GLP- 1 RA/GIP 双受体激动剂治疗成年肥胖患者的指南预计 在 2025 年 8 月或 9 月会出台最终方案。该指南的目的 在于明确 GLP1 药物的临床适应症、应用以及规划方面 的考量，包括这类药物如何以及在何时能够作为包括 临床干预和生活方式干预的慢性病管理模式的一部分 加以应用。减重已成为全社会关注的问题，以 GLP- ...

上述人士的从业背景也正是张斌反对的主要原因。张斌表示，此次被提名的九名董事候选人中，除三名 独立董事外，只有一人具备生物技术及工程学专业底蕴并有IVD行业研发与经营管理经验。 每经记者｜金喆 每经编辑｜陈俊杰 5月9日晚间，达安基因（002030.SZ，股价5.82元，市值81.68亿元）发布公告，当日公司召开了第八届 董事会2025年第三次临时会议。在《关于提名公司第九届董事会非独立董事候选人的预案》中，董事黄 珞和张斌投出反对票。 《每日经济新闻》记者注意到，两人均认为被提名的董事候选人与公司主业匹配度不高。黄珞认为应引 进具备技术前瞻性与商业敏锐度的战略型掌舵人，而不是聘用"同质化纯金融背景为主"的团队。张斌则 表示，新一届董事会在把握行业技术与市场发展方面存在显著的不确定性。 达安基因是国内老牌IVD（体外诊断试剂）企业，主要产品为体外诊断试剂，但在去年出现2004年上市 以来的首次亏损。年报显示，2024年，达安基因营收约8.53亿元，同比下降27.27%，净利润约-9.25亿 元，同比下降983.98%。 5月9日晚间，记者试图联系达安基因相关人士采访，截至发稿未获得回复。 两名董事反对新一届董事 ...

Core Points - The company is holding a shareholder meeting on May 20, 2025, to discuss various agenda items including the independent director's report for 2024 and voting on resolutions [1][2] - The company reported a revenue of 1.585 billion yuan for 2024, a slight decrease of 0.27% compared to the previous year, with a net profit of 100 million yuan, down 5.73% [10][11] - The company has made significant progress in stem cell drug development, with multiple clinical trials approved and ongoing for new treatments [12][22] - The company is focusing on enhancing its governance structure and compliance, having received various quality management certifications [17][18] Company Operations - The board of directors has operated in compliance with relevant laws and regulations, approving 32 resolutions with a 100% approval rate [5][6] - The company has established a governance structure involving the shareholder meeting, board of directors, and supervisory board, ensuring clear responsibilities and effective operation [10] - The company has implemented a comprehensive quality management system, achieving ISO certifications in quality, environmental management, and occupational health and safety [17][18] Financial Performance - The company reported a total asset value of 5.249 billion yuan as of December 31, 2024, a decrease of 3% from the previous year [30] - The company’s cash flow from operating activities was negative 64 million yuan, indicating challenges in cash generation [30] - The company has initiated a share buyback program, repurchasing shares worth 200 million yuan, which is 199.32% of its net profit for the year [31] Future Plans - The company aims to deepen its research and development in stem cell therapies and expand its market presence both domestically and internationally [22][24] - The company plans to enhance its automated production capabilities and improve the efficiency of its cell therapy products [23] - The company is committed to building a comprehensive health management ecosystem for families, integrating various health services and insurance collaborations [25]